Abstract
Alzheimer disease (AD) and Creutzfeldt-Jakob disease (CJD) are sporadic and genetic neurodegenerative conditions characterized by brain accumulation and deposition of protein aggregates. In AD, the key pathogenic event is linked to the formation of a 4-kDa amyloid β (Aβ) peptide, generated by sequential cleavages of the amyloid precursor protein (APP). In CJD and other prion diseases, the process is initiated by conformational changes of the cellular prion protein, or PrPC, into a β-sheet rich isoform, named PrPsc, which acquires protease-resistance and detergent insolubility. Once generated, Aβ and PrPsc are highly prone to misassembly under thermodynamically favourable oligomeric forms and protofibril/fibril structures. The variety of physicochemical states exhibited by Aβ and PrPsc is accounted for by distinct molecular forms with different amino and/or carboxyl termini and alternative conformations. Unlike Aβ, PrPsc is also infectious, and this feature poses public health concerns, as in the case of iatrogenic and variant CJD (vCJD). Several lines of evidence suggest that Aβ and PrPsc are the main factors responsible for death of selected neuronal populations in brains of AD and prion diseases victims. Therefore, in addition to symptomatic treatment of dementia, therapeutic efforts are currently aimed at testing the efficacy of disease-modifying, anti-amyloid therapies. Experimental and clinical therapeutic interventions include passive and active immunization against amyloidogenic peptides, non immunological strategies, as well as drugs enhancing the nonamyloidogenic protein processing. In this review, we focus on molecular mechanisms of AD and prion diseases, and on novel treatment approaches.
Keywords: Alzheimer disease, prion diseases, transmissible spongiform encephalopathies, Creutzfeldt-Jakob disease, amyloid precursor protein, dementia, anti-amyloid therapies, protein-misfolding diseases
Current Medicinal Chemistry
Title: Cerebral Amyloidoses: Molecular Pathways and Therapeutic Challenges
Volume: 13 Issue: 16
Author(s): Salvatore Monaco, Gianluigi Zanusso, Sara Mazzucco and Nicola Rizzuto
Affiliation:
Keywords: Alzheimer disease, prion diseases, transmissible spongiform encephalopathies, Creutzfeldt-Jakob disease, amyloid precursor protein, dementia, anti-amyloid therapies, protein-misfolding diseases
Abstract: Alzheimer disease (AD) and Creutzfeldt-Jakob disease (CJD) are sporadic and genetic neurodegenerative conditions characterized by brain accumulation and deposition of protein aggregates. In AD, the key pathogenic event is linked to the formation of a 4-kDa amyloid β (Aβ) peptide, generated by sequential cleavages of the amyloid precursor protein (APP). In CJD and other prion diseases, the process is initiated by conformational changes of the cellular prion protein, or PrPC, into a β-sheet rich isoform, named PrPsc, which acquires protease-resistance and detergent insolubility. Once generated, Aβ and PrPsc are highly prone to misassembly under thermodynamically favourable oligomeric forms and protofibril/fibril structures. The variety of physicochemical states exhibited by Aβ and PrPsc is accounted for by distinct molecular forms with different amino and/or carboxyl termini and alternative conformations. Unlike Aβ, PrPsc is also infectious, and this feature poses public health concerns, as in the case of iatrogenic and variant CJD (vCJD). Several lines of evidence suggest that Aβ and PrPsc are the main factors responsible for death of selected neuronal populations in brains of AD and prion diseases victims. Therefore, in addition to symptomatic treatment of dementia, therapeutic efforts are currently aimed at testing the efficacy of disease-modifying, anti-amyloid therapies. Experimental and clinical therapeutic interventions include passive and active immunization against amyloidogenic peptides, non immunological strategies, as well as drugs enhancing the nonamyloidogenic protein processing. In this review, we focus on molecular mechanisms of AD and prion diseases, and on novel treatment approaches.
Export Options
About this article
Cite this article as:
Monaco Salvatore, Zanusso Gianluigi, Mazzucco Sara and Rizzuto Nicola, Cerebral Amyloidoses: Molecular Pathways and Therapeutic Challenges, Current Medicinal Chemistry 2006; 13 (16) . https://dx.doi.org/10.2174/092986706777585022
DOI https://dx.doi.org/10.2174/092986706777585022 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Reorganizing Metals: the Use of Chelating Compounds as Potential Therapies for Metal-Related Neurodegenerative Disease
Current Topics in Medicinal Chemistry Genito-Urological Cancers in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Diabetes, Diabetic Complications, and Phosphate Toxicity: A Scoping Review
Current Diabetes Reviews BRI2 Interacts with BACE1 and Regulates Its Cellular Levels by Promoting its Degradation and Reducing Its mRNA Levels
Current Alzheimer Research The Pharmacological Management of Delirium in Critical Illness
Current Drug Therapy Editorial [Hot Topic: Mechanisms of HIV-1 Latency Post HAART Treatment Area (Guest Editors: Lena Al-Harthi and Fatah Kashanchi)]
Current HIV Research The Protective Effects of Natural Products on Blood-Brain Barrier Breakdown
Current Medicinal Chemistry Simvastatin and Other HMG-CoA Reductase Inhibitors on Brain Cholesterol Levels in Alzheimers Disease
Current Alzheimer Research Social Markers of Mild Cognitive Impairment: Proportion of Word Counts in Free Conversational Speech
Current Alzheimer Research Heart Failure Pharmacotherapy and Supports in the Elderly - A Short Review
Current Cardiology Reviews Patent Selections
Recent Patents on Biotechnology Cofilin/Actin Rod Formation by Dysregulation of Cofilin-1 Activity as a Central Initial Step in Neurodegeneration
Mini-Reviews in Medicinal Chemistry Alpha-1-Antichymotrypsin: A Common Player for Type 2 Diabetes and Alzheimer's Disease
Current Diabetes Reviews Mononuclear Phagocyte Accumulation in Visceral Tissue in HIV Encephalitis: Evidence for Increased Monocyte/Macrophage Trafficking and Altered Differentiation
Current HIV Research A Surgical Opinion on Hyperalgesia/Nociception, Inflammatory/Neurogenic Pain and Anti-inflammatory Responses and Drug Interventions Revisited: Current Breakthroughs and Views
Current Immunology Reviews (Discontinued) Differentiating Normal from Pathological Brain Ageing Using Standard Neuropsychological Tests
Current Alzheimer Research Peri-Procedural Care of Renal Nerve Ablation Candidates
Current Clinical Pharmacology Novel Therapies for Schizophrenia: Understanding the Glutamatergic Synapse and Potential Targets for Altering N-methyl-D-aspartate Neurotransmission
Recent Patents on CNS Drug Discovery (Discontinued) Zoledronic Acid Use and Risk of Cognitive Decline among Elderly Women and Men with Osteoporosis
Endocrine, Metabolic & Immune Disorders - Drug Targets Patent Selections :
Recent Patents on CNS Drug Discovery (Discontinued)